Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

News Conference News SCAI 2024

No Sex-Specific Differences in PAD Therapy Outcomes: REVIVE Analysis

May 10, 2024

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

October 25, 2023

CLIPPER Attempts to Draw Out Useful Quality Metrics for CLTI

News Conference News SCAI 2023

CLIPPER Attempts to Draw Out Useful Quality Metrics for CLTI

May 25, 2023

Real-World CLTI Patients, Outcomes Are a Departure From BEST-CLI

News Conference News SCAI 2023

Real-World CLTI Patients, Outcomes Are a Departure From BEST-CLI

May 24, 2023

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

News Conference News AHA 2022

Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI

November 07, 2022

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

News Conference News ESC 2022

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

August 30, 2022

AFFIRM-AHF: IV Iron Supplementation Linked to Fewer Repeat Hospitalizations for HF

News Conference News AHA 2020

AFFIRM-AHF: IV Iron Supplementation Linked to Fewer Repeat Hospitalizations for HF

November 13, 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

April 02, 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

News Conference News ACC 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

March 28, 2020

News Conference News TCT 2016

ILLUMENATE: Low-Dose DCB Bests Angioplasty Alone in Complex Patients With SFA/Popliteal Lesions

November 07, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.